



## **Thomas Meier, PhD**

### **Chief Executive Officer**

Thomas Meier was appointed CEO of Santhera, effective October 1, 2011, after having served seven years as Chief Scientific Officer (CSO) for the Company. Mr Meier was the founder and CEO of MyoContract, a Basel-based research company focused on orphan neuromuscular diseases, which he merged in 2004 with Graffinity of Heidelberg, Germany, to form today's Santhera. In 1999, Mr Meier became an independent research group leader and lecturer in the Department of Pharmacology and Neurobiology at the University of Basel, Switzerland, where he established MyoContract as first start-up of the Biozentrum. Mr Meier received his PhD in biology from the University of Basel, Switzerland, in 1992 and subsequently joined the University of Colorado Health Sciences Center, US. He has a distinguished scientific track record in the field of neuromuscular research. Before joining the industry, Mr Meier was awarded the International Research Fellowship Award from the US National Institutes of Health and a long-term fellowship from the Human Frontier Science Foundation. In 2007, he received the Bio-Valley Basel Award for his outstanding contributions to the life sciences in the area.